---
schema_version: "secwatch.filing_event.v1"
accession: "0001664710-26-000053"
form_type: "8-K"
ticker: "KROS"
cik: "0001664710"
company_name: "Keros Therapeutics, Inc."
filed_at: "2026-09-08T20:02:45+00:00"
generated_at: "2026-09-08T20:04:20.023334+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# Keros authorizes $5M buyback after $20M Takeda milestone for elritercept; cash runway to 2H 2028

## Summary
- Board approved $5 million share repurchase program of KROS common stock, announced September 8, 2026.
- Program follows $20 million development milestone from Takeda Pharmaceuticals triggered by first patient dose in ELRiSE MDS trial of elritercept.
- Repurchases may occur in open market or other means; timing depends on market price and conditions; may be suspended or discontinued.
- Cash and equivalents were $257.6 million as of June 30, 2026; funding runway extended into second half of 2028 after milestone and buyback.
- Milestone confirms elritercept MDS development progress under license agreement with Takeda.

## SEC filing metadata
- accession: 0001664710-26-000053
- form_type: 8-K
- ticker: KROS
- cik: 0001664710
- company_name: Keros Therapeutics, Inc.
- filed_at: 2026-09-08T20:02:45+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1664710/000166471026000053/0001664710-26-000053-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1664710/000166471026000053/kros-20260908.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001664710-26-000053
- JSON: https://secwatch.observer/filing/0001664710-26-000053.json
- Plain text: https://secwatch.observer/filing/0001664710-26-000053.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.